Summit Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for certain lung cancer patients. The FDA determined that the BLA cannot be approved in its current form because the progression-free survival benefit did not establish substantial evidence of effectiveness without a statistically significant improvement in overall survival.
Summit Therapeutics Inc. filed a prospectus supplement to its automatic shelf registration statement on Form S-3 for the potential issuance of common stock. The filing includes a legal opinion from Baker & Hostetler LLP regarding the legality of the shares being offered.
Summit Therapeutics reported a net loss of $613.5 million for the nine months ended September 30, 2026, compared to a net loss of $860.4 million in the prior year period. The company ended the quarter with $629.8 million in cash, cash equivalents, and short-term investments, while total stockholders' equity decreased to $564.7 million from $658.9 million at year-end 2025.
Summit Therapeutics reported its Q3 2026 financial results, highlighting a $2.0 billion strategic equity investment from AstraZeneca received post-quarter. The company ended the period with $629.8 million in cash and is advancing its global clinical development program for ivonescimab across multiple solid tumor indications.
“This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca’s $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others.”
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit
“Our global clinical development program for ivonescimab continues to broaden, with the announcement of ivonescimab combination collaborations with Datroway® and sone-ve, alongside new studies in bladder cancer with HARMONi-GU1, in biliary tract cancer with EA2251, and in kidney cancer with SMT112-216 and Arcus’ ARC- 20 platform study.”
Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit
Summit Therapeutics entered into a securities purchase agreement with AstraZeneca for a $2.0 billion private placement of newly designated Class A Convertible Preferred Stock. The preferred shares are priced at a common stock equivalent of $18.3561 per share and will be used to support the development of ivonescimab, including new clinical collaborations with AstraZeneca's oncology portfolio.
Value
$2B
Counterparty
AstraZeneca Holdings B.V.
“This significant investment, as well as the collaboration, is a powerful validation of the potential of ivonescimab. We are proud to welcome AstraZeneca as a strategic investor as we continue to work with purposeful urgency to make a significant difference for patients with cancer by improving outcomes.”
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics
“The developments announced today with AstraZeneca open an exciting new chapter in the advancement of ivonescimab. With a growing body of evidence supporting ivonescimab’s differentiated PD-1 / VEGF bispecific approach, we look forward to further broadening the development plan of ivonescimab and initiating new clinical trials exploring the potential to combine ivonescimab with promising novel anti-cancer compounds, including ADCs, to bring together complementary approaches to tumor-cell killing, antitumor immunity, and the tumor microenvironment.”
Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics
Summit Therapeutics announced updated overall survival (OS) results from its global Phase III HARMONi trial of ivonescimab in patients with EGFR-mutated non-small cell lung cancer. The updated June 2026 analysis showed a favorable OS hazard ratio of 0.76 in the global population, demonstrating consistent efficacy across both Western and Asian patient subgroups. No new safety signals were observed, reinforcing the potential of ivonescimab as a treatment option following progression on EGFR-targeted therapy.
Summit Therapeutics' partner Akeso presented updated Phase III HARMONi-2 trial data showing ivonescimab monotherapy significantly improved overall survival compared to pembrolizumab in PD-L1-positive advanced NSCLC. Ivonescimab reduced the risk of death by 27% (HR 0.73) and improved median overall survival by 8.2 months (30.8 months vs 22.6 months).